

Contents

Preface XV

A Personal Foreword XVII

List of Contributors XIX

Part I: Concept and Theory

1	The Concept of Fragment-based Drug Discovery	3
	<i>Daniel A. Erlanson and Wolfgang Jahnke</i>	
1.1	Introduction	3
1.2	Starting Small: Key Features of Fragment-based Ligand Design	4
1.2.1	FBS Samples Higher Chemical Diversity	4
1.2.2	FBS Leads to Higher Hit Rates	5
1.2.3	FBS Leads to Higher Ligand Efficiency	6
1.3	Historical Development	6
1.4	Scope and Overview of this Book	7
	References	9
2	Multivalency in Ligand Design	11
	<i>Vijay M. Krishnamurthy, Lara A. Estroff, and George M. Whitesides</i>	
2.1	Introduction and Overview	11
2.2	Definitions of Terms	12
2.3	Selection of Key Experimental Studies	16
2.3.1	Trivalency in a Structurally Simple System	17
2.3.2	Cooperativity (and the Role of Enthalpy) in the “Chelate Effect”	18
2.3.3	Oligovalency in the Design of Inhibitors to Toxins	18
2.3.4	Bivalency at Well Defined Surfaces (Self-assembled Monolayers, SAMs)	18
2.3.5	Polyvalency at Surfaces of Viruses, Bacteria, and SAMs	18
2.4	Theoretical Considerations in Multivalency	19
2.4.1	Survey of Thermodynamics	19
2.4.2	Additivity and Multivalency	19

2.4.3	Avidity and Effective Concentration (C_{eff})	22
2.4.4	Cooperativity is Distinct from Multivalency	24
2.4.5	Conformational Entropy of the Linker between Ligands	25
2.4.6	Enthalpy/Entropy Compensation Reduces the Benefit of Multivalency	26
2.5	Representative Experimental Studies	26
2.5.1	Experimental Techniques Used to Examine Multivalent Systems	26
2.5.1.1	Isothermal Titration Calorimetry	26
2.5.1.2	Surface Plasmon Resonance Spectroscopy	27
2.5.1.3	Surface Assays Using Purified Components (Cell-free Assays)	27
2.5.1.4	Cell-based Surface Assays	27
2.5.2	Examination of Experimental Studies in the Context of Theory	28
2.5.2.1	Trivalency in Structurally Simple Systems	28
2.5.2.2	Cooperativity (and the Role of Enthalpy) in the “Chelate Effect”	29
2.5.2.3	Oligovalency in the Design of Inhibitors of Toxins	29
2.5.2.4	Bivalency in Solution and at Well Defined Surfaces (SAMs)	30
2.5.2.5	Polyvalency at Surfaces (Viruses, Bacteria, and SAMs)	31
2.6	Design Rules for Multivalent Ligands	32
2.6.1	When Will Multivalency Be a Successful Strategy to Design Tight-binding Ligands?	32
2.6.2	Choice of Scaffold for Multivalent Ligands	33
2.6.2.1	Scaffolds for Oligovalent Ligands	33
2.6.2.2	Scaffolds for Polyvalent Ligands	35
2.6.3	Choice of Linker for Multivalent Ligands	36
2.6.3.1	Rigid Linkers Represent a Simple Approach to Optimize Affinity	36
2.6.3.2	Flexible Linkers Represent an Alternative Approach to Rigid Linkers to Optimize Affinity	37
2.6.4	Strategy for the Synthesis of Multivalent Ligands	37
2.6.4.1	Polyvalent Ligands: Polymerization of Ligand Monomers	38
2.6.4.2	Polyvalent Ligands: Functionalization with Ligands after Polymerization	38
2.7	Extensions of Multivalency to Lead Discovery	39
2.7.1	Hetero-oligovalency Is a Broadly Applicable Concept in Ligand Design	39
2.7.2	Dendrimers Present Opportunities for Multivalent Presentation of Ligands	40
2.7.3	Bivalency in the Immune System	40
2.7.4	Polymers Could Be the Most Broadly Applicable Multivalent Ligands	42
2.8	Challenges and Unsolved Problems in Multivalency	44
2.9	Conclusions	44
	Acknowledgments	45
	References	45

3	Entropic Consequences of Linking Ligands	55
	<i>Christopher W. Murray and Marcel L. Verdonk</i>	
3.1	Introduction	55
3.2	Rigid Body Barrier to Binding	55
3.2.1	Decomposition of Free Energy of Binding	55
3.2.2	Theoretical Treatment of the Rigid Body Barrier to Binding	56
3.3	Theoretical Treatment of Fragment Linking	57
3.4	Experimental Examples of Fragment Linking Suitable for Analysis	59
3.5	Estimate of Rigid Body Barrier to Binding	61
3.6	Discussion	62
3.7	Conclusions	64
	References	65
4	Location of Binding Sites on Proteins by the Multiple Solvent Crystal Structure Method	67
	<i>Dagmar Ringe and Carla Mattos</i>	
4.1	Introduction	67
4.2	Solvent Mapping	68
4.3	Characterization of Protein–Ligand Binding Sites	69
4.4	Functional Characterization of Proteins	71
4.5	Experimental Methods for Locating the Binding Sites of Organic Probe Molecules	71
4.6	Structures of Elastase in Nonaqueous Solvents	72
4.7	Organic Solvent Binding Sites	73
4.8	Other Solvent Mapping Experiments	75
4.9	Binding of Water Molecules to the Surface of a Protein	78
4.10	Internal Waters	79
4.11	Surface Waters	80
4.12	Conservation of Water Binding Sites	81
4.13	General Properties of Solvent and Water Molecules on the Protein	82
4.14	Computational Methods	83
4.15	Conclusion	85
	Acknowledgments	85
	References	85

Part 2: Fragment Library Design and Computational Approaches

5	Cheminformatics Approaches to Fragment-based Lead Discovery	91
	<i>Tudor I. Oprea and Jeffrey M. Blaney</i>	
5.1	Introduction	91
5.2	The Chemical Space of Small Molecules (Under 300 a.m.u.)	92
5.3	The Concept of Lead-likeness	94
5.4	The Fragment-based Approach in Lead Discovery	96
5.5	Literature-based Identification of Fragments: A Practical Example	99

5.6	Conclusions	107
	Acknowledgments	109
	References	109
6	Structural Fragments in Marketed Oral Drugs	113
	<i>Michal Vieth and Miles Siegel</i>	
6.1	Introduction	113
6.2	Historical Look at the Analysis of Structural Fragments of Drugs	113
6.3	Methodology Used in this Analysis	115
6.4	Analysis of Similarities of Different Drug Data Sets Based on the Fragment Frequencies	118
6.5	Conclusions	123
	Acknowledgments	124
	References	124
7	Fragment Docking to Proteins with the Multi-copy Simultaneous Search Methodology	125
	<i>Collin M. Stultz and Martin Karplus</i>	
7.1	Introduction	125
7.2	The MCSS Method	125
7.2.1	MCSS Minimizations	126
7.2.2	Choice of Functional Groups	126
7.2.3	Evaluating MCSS Minima	127
7.3	MCSS in Practice: Functionality Maps of Endothiapepsin	132
7.4	Comparison with GRID	135
7.5	Comparison with Experiment	137
7.6	Ligand Design with MCSS	138
7.6.1	Designing Peptide-based Ligands to Ras	138
7.6.2	Designing Non-peptide Based Ligands to Cytochrome P450	140
7.6.3	Designing Targeted Libraries with MCSS	140
7.7	Protein Flexibility and MCSS	141
7.8	Conclusion	143
	Acknowledgments	144
	References	144

Part 3: Experimental Techniques and Applications

8	NMR-guided Fragment Assembly	149
	<i>Daniel S. Sem</i>	
8.1	Historical Developments Leading to NMR-based Fragment Assembly	149
8.2	Theoretical Foundation for the Linking Effect	150
8.3	NMR-based Identification of Fragments that Bind Proteins	152
8.3.1	Fragment Library Design Considerations	152

8.3.2	The “SHAPES” NMR Fragment Library	154
8.3.3	The “SAR by NMR” Fragment Library	156
8.3.4	Fragment-based Classification of protein Targets	160
8.4	NMR-based Screening for Fragment Binding	163
8.4.1	Ligand-based Methods	163
8.4.2	Protein-based Methods	165
8.4.3	High-throughput Screening: Traditional and TINS	167
8.5	NMR-guided Fragment Assembly	167
8.5.1	SAR by NMR	167
8.5.2	SHAPES	169
8.5.3	Second-site Binding Using Paramagnetic Probes	169
8.5.4	NMR-based Docking	170
8.6	Combinatorial NMR-based Fragment Assembly	171
8.6.1	NMR SOLVE	171
8.6.2	NMR ACE	173
8.7	Summary and Future Prospects	176
	References	177
9	SAR by NMR: An Analysis of Potency Gains Realized Through Fragment-linking and Fragment-elaboration Strategies for Lead Generation	181
	<i>Philip J. Hajduk, Jeffrey R. Huth, and Chaohong Sun</i>	
9.1	Introduction	181
9.2	SAR by NMR	182
9.3	Energetic Analysis of Fragment Linking Strategies	183
9.4	Fragment Elaboration	187
9.5	Energetic Analysis of Fragment Elaboration Strategies	188
9.6	Summary	190
	References	191
10	Pyramid: An Integrated Platform for Fragment-based Drug Discovery	193
	<i>Thomas G. Davies, Rob L. M. van Montfort, Glyn Williams, and Harren Jhoti</i>	
10.1	Introduction	193
10.2	The Pyramid Process	194
10.2.1	Introduction	194
10.2.2	Fragment Libraries	195
10.2.2.1	Overview	195
10.2.2.2	Physico-chemical Properties of Library Members	196
10.2.2.3	Drug Fragment Library	197
10.2.2.4	Privileged Fragment Library	197
10.2.2.5	Targeted Libraries and Virtual Screening	197
10.2.2.6	Quality Control of Libraries	201
10.2.3	Fragment Screening	201
10.2.4	X-ray Data Collection	202

10.2.5	Automation of Data Processing	203
10.2.6	Hits and Diversity of Interactions	205
10.2.6.1	Example 1: Compound 1 Binding to CDK2	205
10.2.6.2	Example 2: Compound 2 Binding to p38 α	207
10.2.6.3	Example 3: Compound 3 Binding to Thrombin	207
10.3	Pyramid Evolution – Integration of Crystallography and NMR	207
10.3.1	NMR Screening Using Water-LOGSY	208
10.3.2	Complementarity of X-ray and NMR Screening	210
10.4	Conclusions	211
	Acknowledgments	211
	References	212

11 **Fragment-based Lead Discovery and Optimization Using X-Ray Crystallography, Computational Chemistry, and High-throughput Organic Synthesis** 215

Jeff Blaney, Vicki Nienaber, and Stephen K. Burley

11.1	Introduction	215
11.2	Overview of the SGX Structure-driven Fragment-based Lead Discovery Process	217
11.3	Fragment Library Design for Crystallographic Screening	218
11.3.1	Considerations for Selecting Fragments	218
11.3.2	SGX Fragment Screening Library Selection Criteria	219
11.3.3	SGX Fragment Screening Library Properties	220
11.3.4	SGX Fragment Screening Library Diversity: Theoretical and Experimental Analyses	220
11.4	Crystallographic Screening of the SGX Fragment Library	221
11.4.1	Overview of Crystallographic Screening	222
11.4.2	Obtaining the Initial Target Protein Structure	224
11.4.3	Enabling Targets for Crystallographic Screening	225
11.4.4	Fragment Library Screening at SGX-CAT	225
11.4.5	Analysis of Fragment Screening Results	226
11.4.6	Factor VIIa Case Study of SGX Fragment Library Screening	228
11.5	Complementary Biochemical Screening of the SGX Fragment Library	230
11.6	Importance of Combining Crystallographic and Biochemical Fragment Screening	232
11.7	Selecting Fragments Hits for Chemical Elaboration	233
11.8	Fragment Optimization	234
11.8.1	Spleen Tyrosine Kinase Case Study	234
11.8.2	Fragment Optimization Overview	240
11.8.3	Linear Library Optimization	241
11.8.4	Combinatorial Library Optimization	242
11.9	Discussion and Conclusions	243
11.10	Postscript: SGX Oncology Lead Generation Program	245
	References	245

12	Synergistic Use of Protein Crystallography and Solution-phase NMR Spectroscopy in Structure-based Drug Design: Strategies and Tactics	249
	<i>Cele Abad-Zapatero, Geoffrey F. Stamper, and Vincent S. Stoll</i>	
12.1	Introduction	249
12.2	Case 1: Human Protein Tyrosine Phosphatase	252
12.2.1	Designing and Synthesizing Dual-site Inhibitors	252
12.2.1.1	The Target	252
12.2.1.2	Initial Leads	252
12.2.1.3	Extension of the Initial Fragment	254
12.2.1.4	Discovery and Incorporation of the Second Fragment	256
12.2.1.5	The Search for Potency and Selectivity	257
12.2.2	Finding More “Drug-like” Molecules	258
12.2.2.1	Decreasing Polar Surface Area on Site 2	258
12.2.2.2	Monoacid Replacements on Site 1	258
12.2.2.3	Core Replacement	259
12.3	Case 2: MurF	261
12.3.1	Pre-filtering by Solution-phase NMR for Rapid Co-crystal Structure Determinations	261
12.3.1.1	The Target	261
12.3.1.2	Triage of Initial Leads	261
12.3.1.3	Solution-phase NMR as a Pre-filter for Co-crystallization Trials	262
12.4	Conclusion	263
	Acknowledgments	264
	References	264
13	Ligand SAR Using Electrospray Ionization Mass Spectrometry	267
	<i>Richard H. Griffey and Eric E. Swayze</i>	
13.1	Introduction	267
13.2	ESI-MS of Protein and RNA Targets	268
13.2.1	ESI-MS Data	268
13.2.2	Signal Abundances	268
13.3	Ligands Selected Using Affinity Chromatography	271
13.3.1	Antibiotics Binding Bacterial Cell Wall Peptides	272
13.3.2	Kinases and GPCRs	272
13.3.3	Src Homology 2 Domain Screening	273
13.3.4	Other Systems	274
13.4	Direct Observation of Ligand–Target Complexes	275
13.4.1	Observation of Enzyme–Ligand Transition State Complexes	276
13.4.2	Ligands Bound to Structured RNA	276
13.4.3	ESI-MS for Linking Low-affinity Ligands	277
13.5	Unique Features of ESI-MS Information for Designing Ligands	282
	References	282

14	Tethering	285
	<i>Daniel A. Erlanson, Marcus D. Ballinger, and James A. Wells</i>	
14.1	Introduction	285
14.2	Energetics of Fragment Selection in Tethering	286
14.3	Practical Considerations	289
14.4	Finding Fragments	289
14.4.1	Thymidylate Synthase: Proof of Principle	289
14.4.2	Protein Tyrosine Phosphatase 1B: Finding Fragments in a Fragile, Narrow Site	292
14.5	Linking Fragments	293
14.5.1	Interleukin-2: Use of Tethering to Discover Small Molecules that Bind to a Protein–Protein Interface	293
14.5.2	Caspase-3: Finding and Combining Fragments in One Step	296
14.5.3	Caspase-1	299
14.6	Beyond Traditional Fragment Discovery	300
14.6.1	Caspase-3: Use of Tethering to Identify and Probe an Allosteric Site	300
14.6.2	GPCRs: Use of Tethering to Localize Hits and Confirm Proposed Binding Models	303
14.7	Related Approaches	306
14.7.1	Disulfide Formation	306
14.7.2	Imine Formation	307
14.7.3	Metal-mediated	307
14.8	Conclusions	308
	Acknowledgments	308
	References	308

Part 4: Emerging Technologies in Chemistry

15	Click Chemistry for Drug Discovery	313
	<i>Stefanie Röper and Hartmuth C. Kolb</i>	
15.1	Introduction	313
15.2	Click Chemistry Reactions	314
15.3	Click Chemistry in Drug Discovery	316
15.3.1	Lead Discovery Libraries	316
15.3.2	Natural Products Derivatives and the Search for New Antibiotics	317
15.3.3	Synthesis of Neoglycoconjugates	320
15.3.4	HIV Protease Inhibitors	321
15.3.5	Synthesis of Fucosyltransferase Inhibitor	323
15.3.6	Glycoarrays	324
15.4	<i>In Situ</i> Click Chemistry	325
15.4.1	Discovery of Highly Potent AChE by <i>In Situ</i> Click Chemistry	325
15.5	Bioconjugation Through Click Chemistry	328
15.5.1	Tagging of Live Organisms and Proteins	328

15.5.2	Activity-based Protein Profiling	330
15.5.3	Labeling of DNA	332
15.5.4	Artificial Receptors	333
15.6	Conclusion	334
	References	335
16	Dynamic Combinatorial Diversity in Drug Discovery	341
	<i>Matthias Hochgürtel and Jean-Marie Lehn</i>	
16.1	Introduction	341
16.2	Dynamic Combinatorial Chemistry – The Principle	342
16.3	Generation of Diversity: DCC Reactions and Building Blocks	343
16.4	DCC Methodologies	346
16.5	Application of DCC to Biological Systems	347
16.5.1	Enzymes as Targets	349
16.5.2	Receptor Proteins as Targets	355
16.5.3	Nucleotides as Targets	357
16.6	Summary and Outlook	359
	References	361
	Index	365